Rystiggo MG denied as non-formulary by Cigna?

Cigna's specific coverage criteria for rystiggo mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rystiggo (rozanolixizumab-noli) as Non-Formulary — and Why You Can Appeal

Cigna maintains a tiered drug formulary and may deny Rystiggo for generalized myasthenia gravis (gMG) because it is not included on the plan's covered formulary list, or is placed on a tier requiring medical exception before coverage applies. Non-formulary denials for specialty biologics like Rystiggo are common and frequently reversible through a formulary exception process — particularly when formulary alternatives either have not been tried, were tried and failed, or are clinically contraindicated for the specific patient. Cigna's own exception process exists precisely for this scenario.

## Your Appeal Rights

Under ACA Section 2719, non-grandfathered plans must provide independent external review of adverse benefit determinations, including non-formulary denials, after internal appeals are exhausted. ERISA Section 503 requires written, specific justification for any denial of a claim. A formulary exception request is the first and often fastest path — this is separate from but may proceed in parallel with a formal appeal. If the patient's clinical situation is urgent, expedited processing of both the exception and the appeal is available. The external review window is generally available for roughly four months after exhausting internal remedies.

## The Appeal Process and Timeline

1. Request a formulary exception from Cigna immediately — this is an administrative request that can be submitted by the prescribing neurologist directly and is often decided within days. 2. If the exception is denied, file a first-level internal appeal within the timeframe on the denial notice, attaching clinical documentation. 3. If denied internally, escalate to external review. External reviewers assess whether the non-formulary determination is consistent with your plan terms and applicable law. 4. In parallel, ask Cigna to identify all formulary alternatives for gMG — this information is legally required — so you can specifically document why each alternative was tried, failed, or is inappropriate.

## Documentation to Gather

• Formulary exception request letter: from the treating neurologist, stating the diagnosis, the formulary alternatives Cigna would cover for gMG, and why each alternative is medically inappropriate for this patient.
• Trial and failure records: documentation of any formulary gMG therapies already tried, with dates, clinical response, and reasons for discontinuation.
• Contraindication documentation: if formulary alternatives are contraindicated by comorbidity or prior adverse reaction, the relevant chart notes and neurologist explanation.
• Diagnosis and disease severity: records confirming gMG, antibody status, and severity to establish the clinical need for effective treatment.
• Prescribing label: the FDA-approved prescribing information for Rystiggo, to show alignment between the labeled indication and the patient's diagnosis.

## Criteria-Mapping Structure

Obtain the list of formulary alternatives Cigna offers for gMG biologics. Create a table with each alternative in the left column and the specific clinical reason it is inappropriate for this patient in the right column — whether due to prior failure, contraindication, or another clinical factor. This direct comparison is the core of a successful formulary exception appeal and gives the reviewer a structured basis for approving coverage of Rystiggo as the medically necessary option.